November 28, 2020
1 min read
Save

NuVasive receives FDA clearance for thoracolumbar interbody portfolio

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NuVasive Inc. has received FDA 510(k) clearance for its portfolio of static and expandable thoracolumbar interbody implants for the treatment of sagittal malalignment and deformities of the spine, according to a press release.

The company’s thoracolumbar portfolio, which includes the Cohere, Modulus, TLX, MLX and CoRoent implants, will help NuVasive expand into multi-level spine surgery, according to the release.

“NuVasive’s thoracolumbar interbodies are now the only implants on the market to be clinically validated in and indicated for the treatment of sagittal deformities,” Massimo Calafiore, executive vice president of global business units at NuVasive, said in the release. “This clearance is reflective of NuVasive’s leadership in the field of global spinal alignment and reflects the company’s commitment to providing procedural solutions that help improve patient outcomes through the preservation and restoration of sagittal alignment.”